TFFP - TFF Pharmaceuticals Inc Stock Price, Fair Value and News

$0.060.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TFFP Price Action

Last 7 days

-79.3%

Last 30 days

-96.4%

Last 90 days

-97.3%

Trailing 12 Months

-99.3%

TFFP RSI Chart

TFFP Valuation

Market Cap

266.6K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.23

Price/Free Cashflow

-0.02

TFFP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TFFP Fundamentals

TFFP Revenue

Revenue (TTM)

1.2M

Rev. Growth (Yr)

-17.62%

Rev. Growth (Qtr)

-70.26%

TFFP Earnings

Earnings (TTM)

-18.5M

Earnings Growth (Yr)

19.6%

Earnings Growth (Qtr)

20.86%

TFFP Profitability

Return on Equity

-590.38%

Return on Assets

-261.68%

Free Cashflow Yield

-4.8K%

TFFP Investor Care

Shares Dilution (1Y)

87.84%

Diluted EPS (TTM)

-5.8

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	885.7K	1.2M	1.2M	0
2023	479.8K	785.1K	932.3K	733.9K
2022	131.3K	157.4K	195.0K	495.8K
2021	0	0	0	88.2K

Get all data in R, Python etc through our Historical Stock Data APIs

About TFF Pharmaceuticals Inc

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

CEO	Dr. Harlan F. Weisman
WEBSITE	https://tffpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	15

TFF Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for TFF Pharmaceuticals Inc? What does TFFP stand for in stocks?

TFFP is the stock ticker symbol of TFF Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TFF Pharmaceuticals Inc (TFFP)?

As of Thu Dec 19 2024, market cap of TFF Pharmaceuticals Inc is 266.58 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TFFP stock?

You can check TFFP's fair value in chart for subscribers.

Is TFF Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TFFP is over valued or under valued. Whether TFF Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact TFF Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TFFP.

What is TFF Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, TFFP's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TFFP PE ratio will change depending on the future growth rate expectations of investors.